CRISPR/Cas9 gene editors in the green on Gilead deal interest – Seeking Alpha
NormanObserver.com |
CRISPR/Cas9 gene editors in the green on Gilead deal interest
Seeking Alpha The up move in biotechs notwithstanding, CRISPR/Cas9 gene editing players Intellia Therapeutics (NTLA +6.1%), Editas Medicine (EDIT +1.5%) and CRISPR Therapeutics (CRSP +15%) are all seeing increased interest on the heels of comments made by Gilead … Analysts Expect Intellia Therapeutics Inc (NTLA) to Post -$0.43 EPS |
